Seeglim VG2

Optimal Glycemic Control

• FPG reduction by 55 mg/dl
• Decreases PPHG by 80 mg/dl
• Reduces HbA1c by ~1.4%

Reduces Glycemic Variability

• Inhibits overwork of β cells
• Lowers daily glycemic excursions

Intensive Treatment Delays Long-Term
Micro & Macro Vascular Complications

• Cardio Vascular
• Neuropathy
• Nephropathy
• Retinopathy
• Peripheral Vascular Diseases

Safety Parameters

• Lesser risk of Hypoglycemia
• Reduces risk of Weight gain
• No risk of pedal Oedema
• Shows significant reduction in TG & increase in HDL levels